Skip to content

Janux Therapeutics Inc

JANX

Latest QuantConomy context for JANX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
19
Asset profile

Janux Therapeutics Inc

QuantConomy has a structured record for JANX. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
JANX
Name
Janux Therapeutics Inc
Coverage
3 market/data records
Sources
fmp alpaca alphavantage sec nasdaq
Latest signal rows

Recent signals for JANX

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
other event
neutral
70
Jun 23, 08:10 PM JANX filed 8-K: Other Events - 1 material event - [strong neutral signal]
earnings release
neutral
40
Feb 26, 12:00 AM JANX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-26. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
ten percent owner
neutral
37
Jun 13, 12:40 AM RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner) was granted JANX shares ($0.00M) - 5500 shares - [weak neutral signal]

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

PRICE signals are experimental: realized 30-day directional accuracy is ~18% (short-horizon price moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.

Market coverage

Market Exchange Source Asset record
JANX NASDAQ fmp Janux Therapeutics, Inc.
JANX NASDAQ alpaca Janux Therapeutics, Inc. Common Stock
JANX NASDAQ alphavantage Janux Therapeutics Inc

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
2
Rows
19
Date Insider Role Type Shares Price Value Filing
Jul 8, 2026 Campbell David Alan President and CEO exercise 7,000 $4.21 $29,470 4 on EDGAR
Jun 11, 2026 CAPPS VICKIE L Director grant 5,500 $0.00 $0 4 on EDGAR
Jun 11, 2026 Hernday Natasha Director grant 5,500 $0.00 $0 4 on EDGAR
Jun 11, 2026 DOBMEIER ERIC Director grant 5,500 $0.00 $0 4 on EDGAR
Jun 11, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner grant 5,500 $0.00 $0 4 on EDGAR
Jun 11, 2026 Barrett Ronald W Director grant 5,500 $0.00 $0 4 on EDGAR
Jun 11, 2026 Kung Winston Director grant 5,500 $0.00 $0 4 on EDGAR
Jun 2, 2026 Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr sale 4,059 $14.03 $56,944 4 on EDGAR
May 11, 2026 Dobek Maria Vice President, Accounting sale 2,038 $14.17 $28,878 4 on EDGAR
Feb 2, 2026 Go William Chief Medical Officer grant 44,000 $0.00 $0 4 on EDGAR
Jan 2, 2026 Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr grant 36,000 $0.00 $0 4 on EDGAR
Jan 2, 2026 Campbell David Alan President and CEO sale 8,072 $13.73 $110,829 4 on EDGAR
Jan 2, 2026 McIver Zachariah Chief Medical Officer sale 2,714 $13.73 $37,263 4 on EDGAR
Jan 2, 2026 Dobek Maria Vice President, Accounting sale 1,462 $13.73 $20,073 4 on EDGAR
Jan 2, 2026 Meyer Andrew Hollman Chief Business Officer sale 1,879 $13.73 $25,799 4 on EDGAR
Jan 2, 2026 Winter Charles M. Chief Technical Officer sale 2,401 $13.73 $32,966 4 on EDGAR
Jan 2, 2026 DiRaimondo Thomas Chief Scientific Officer sale 2,505 $13.73 $34,394 4 on EDGAR
Dec 1, 2025 Meyer Andrew Hollman Chief Business Officer exercise 3,333 $10.59 $35,296 4 on EDGAR
Nov 14, 2025 Meyer Andrew Hollman Chief Business Officer exercise 3,333 $10.59 $35,296 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query JANX context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access